Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Frequently asked questions
What sector does Oruka Therapeutics, Inc. (ORKA) operate in?
Oruka Therapeutics, Inc. belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Oruka Therapeutics, Inc. (ORKA) current stock price?
As of the latest data, Oruka Therapeutics, Inc. stock price is $108.12, with a previous close of $107.40. Oruka Therapeutics, Inc. gained $0.72 in the last trading session, representing a 0.67% increase.
What is Oruka Therapeutics, Inc. (ORKA) current market capitalization?
Oruka Therapeutics, Inc. market cap is approximately 7.16 billion.
What is Oruka Therapeutics, Inc. (ORKA) Earnings Per Share (EPS)?
The trailing EPS is -$1.93, and the forward EPS is -$2.77.
What is Oruka Therapeutics, Inc. (ORKA) EBITDA?
Oruka Therapeutics, Inc. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -31.78 million.
Does Oruka Therapeutics, Inc. (ORKA) pay dividends?
No. Oruka Therapeutics, Inc. does not pay a dividend.
What is Oruka Therapeutics, Inc. (ORKA) beta (volatility) score?
Oruka Therapeutics, Inc. has a beta of 0.326, indicating lower volatility than the overall market.
